論文・総説 - 辻　耕平

1. Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, Takamune N, Kishimoto N, Hattori SI, Ishii T, Kobayakawa T, Nakano K, Shimizu Y, Das D, Saruwatari J, Hasegawa K, Murayama K, Sukenaga Y, Takamatsu Y, Yoshimura K, Aoki M, Furusawa Y, Okamura T, Yamayoshi S, Kawaoka Y, Misumi S, Tamamura H, Mitsuya H. An orally available P1'-5-fluorinated M(pro) inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. PNAS nexus. 2025.01; 4 (1): pgae578. ( PubMed, DOI )

2. Shinohara K, Kobayakawa T, Tsuji K, Takamatsu Y, Mitsuya H, Tamamura H. Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2. European journal of medicinal chemistry. 2024.12; 280 116963. ( PubMed, DOI )

3. Tsuji K, Tamamura H, Burke TR. Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein. Bioorganic & medicinal chemistry. 2024.12; 119 118055. ( PubMed, DOI )

4. Kobayakawa T, Tsuji K, Tamamura H. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres. Bioorganic & medicinal chemistry. 2024.08; 110 117811.

5. Kobayakawa T, Tsuji K, Tamamura H. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres. Bioorganic & medicinal chemistry. 2024.08; 110 117811. ( PubMed, DOI )

6. Tsuji Kohei, Tamamura Hirokazu, Burke Jr. Terrence R.. Polo like kinase 2とpolo like kinase 3に対する蛍光回復に基づくポロ様キナーゼ1の結合測定法の応用(Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3) Biological & Pharmaceutical Bulletin. 2024.07; 47 (7): 1282-1287. ( 医中誌 )

7. Tsuji K, Tamamura H, Burke TR Jr. Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. RSC chemical biology. 2024.07; 5 (8): 721-728. ( PubMed, DOI )

8. Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, Tsuji K, Ohashi N, Yoshimura K, Nomura W, Mitsuya H, Maeda K, Tamamura H. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS infectious diseases. 2024.06; 10 (6): 2250-2261. ( PubMed, DOI )

9. Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, Ishii T, Miura Y, Nishimura S, Shinohara K, Yamamoto K, Bolah P, Kotani O, Murakami T, Sato H, Tamamura H. Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins. Chemical & pharmaceutical bulletin. 2024; 72 (1): 41-47. ( PubMed, DOI )

10. Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, Nomura W, Furuta T, Tamamura H. Effect of Two-Photon Excitation to 8-Azacoumarin Derivatives as Photolabile Protecting Groups. Chemical & pharmaceutical bulletin. 2024; 72 (3): 311-312. ( PubMed, DOI )

11. Tsuji K, Tamamura H, Burke TR Jr. Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3. Biological & pharmaceutical bulletin. 2024; 47 (7): 1282-1287. ( PubMed, DOI )

12. Kohei Tsuji, Takuya Kobayakawa, Takahiro Ishii, Nobuyo Higashi-Kuwata, Chika Azuma, Kouki Shinohara, Yutaro Miura, Kenichi Yamamoto, Soshi Nishimura, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura. Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement. Chemical and Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( PubMed, DOI )

13. Tsuji Kohei, Kobayakawa Takuya, Ishii Takahiro, Higashi-Kuwata Nobuyo, Azuma Chika, Shinohara Kouki, Miura Yutaro, Yamamoto Kenichi, Nishimura Soshi, Hattori Shin-ichiro, Bulut Haydar, Mitsuya Hiroaki, Tamamura Hirokazu. ハロゲン導入およびアミド結合置換によるSARS-CoV-2のメインプロテアーゼに有効な阻害薬の探索研究(Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement) Chemical & Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( 医中誌 )

14. Takuya Kobayakawa, Masayuki Amano, Miyuki Nakayama, Kohei Tsuji, Takahiro Ishii, Yutaro Miura, Kouki Shinohara, Kenichi Yamamoto, Masao Matsuoka, Hirokazu Tamamura. Development of anti-HBV agents targeting HBV capsid proteins. RSC Medicinal Chemistry. 2023.10; 14 (10): 1973-1980. ( PubMed, DOI )

15. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Kouki Shinohara, Chika Azuma, Yutaro Miura, Hiroki Nakano, Naoya Wada, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura. Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties. Journal of Medicinal Chemistry. 2023.10; 66 (19): 13516-13529. ( PubMed, DOI )

16. Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kohei Tsuji, Nami Ohashi, Shingo Nakahata, Airi Noborio, Kazuhisa Yoshimura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity. European Journal of Medicinal Chemistry. 2023.08; 256 115449. ( PubMed, DOI )

17. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Yutaro Miura, Takahiro Ishii, Kouki Shinohara, Takuya Kobayakawa, Akino Emi, Takashi Nakano, Youichi Suzuki, Hirokazu Tamamura . Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2 RSC Advances. 2023.03; 13 8779-8793.

18. Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai, Hiromi Ogata-Aoki, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Nobutoki Takamune, Naoki Kishimoto, Shin-Ichiro Hattori, Debananda Das, Yukari Uemura, Yosuke Shimizu, Manabu Aoki, Kazuya Hasegawa, Satoshi Suzuki, Akie Nishiyama, Junji Saruwatari, Yukiko Shimizu, Yoshikazu Sukenaga, Yuki Takamatsu, Kiyoto Tsuchiya, Kenji Maeda, Kazuhisa Yoshimura, Shun Iida, Seiya Ozono, Tadaki Suzuki, Tadashi Okamura, Shogo Misumi, Yoshihiro Kawaoka, Hirokazu Tamamura, Hiroaki Mitsuya. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023.02; 14 (1): 1076. ( PubMed, DOI )

19. Kanako Matsuura, Mizuki Yamaura, Hiromi Sakawaki, Ai Himeno, Yalcin Pisil, Takuya Kobayakawa, Kohei Tsuji, Hirokazu Tamamura, Shuzo Matsushita, Tomoyuki Miura. Sensitivity to a CD4 mimic of a consensus clone of monkey-adapted CCR5-tropic SHIV-MK38C. Virology. 2023.01; 578 171-179. ( PubMed, DOI )

20. Rongyi Wang, Kohei Tsuji, Takuya Kobayakawa, Yishan Liu, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors Bioorganic & Medicinal Chemistry. 2022.12; 76 117083. ( PubMed, DOI )